Skip to content

Study · Animal study (in vivo) · rat · 2021

5 results

Activation of glucagon-like peptide-1 receptors and skilled reach foraging.

Vestlund J, Bergquist F, Licheri V, Adermark L, Jerlhag E

Addiction biology8 Aug 2020Cited by 6 (Europe PMC)

PMID32770792 (opens in a new tab)PMCIDPMC8244104 (opens in a new tab)DOI10.1111/adb.12953 (opens in a new tab)PepBankPUB-32770792
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exendin-4 (Ex4), liraglutide and dulaglutide, regulate glucose homeostasis and are thus used to treat diabetes type II. GLP-1 also contributes towards a variety of additional physiological functions, including suppression of reward and improvement of learning. Acute activation of GLP-1R in the nucleus accumbens (NAc) shell, an area essential for motivation, reduces the motivation to consume sucrose or alcohol when assessed in a simple motor task. However, the effects of repeated administration of the different GLP-1R agonists on behaviours in a more complex motor task are unknown. The aim was therefore to investigate the effects of repeated Ex4, liraglutide or dulaglutide on the motivation and learning of a complex motor tasks such as skilled reach foraging in the Montoya staircase test. To explore the neurophysiological correlates of the different GLP-1R agonists on motivation, ex vivo electrophysiological recordings were conducted. In rats with an acquired skilled reach performance, Ex4 or liraglutide but not dulaglutide reduced the motivation of skilled reach foraging. In trained rats, Ex4 infusion into NAc shell decreased this motivated behaviour, and both Ex4 and liraglutide supressed the evoked field potentials in NAc shell. In rats without prior Montoya experience, dulaglutide but not Ex4 or liraglutide enhanced the learning of skilled reach foraging. Taken together, these findings indicate that the tested GLP-1R agonists have different behavioural outcomes depending on the context.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In trained rats, dulaglutide did not reduce skilled reach foraging motivation.

    In plain wordsIn trained rats, dulaglutide did not reduce motivation to reach for food.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSkilled reach motivation
    Study

    ratn: not reported in source

    Montoya staircase skilled reach test
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In rats with an acquired skilled reach performance, Ex4 or liraglutide but not dulaglutide reduced the motivation of skilled reach foraging.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In trained rats, liraglutide reduced skilled reach foraging motivation.

    In plain wordsIn trained rats, liraglutide reduced motivation to reach for food.

    Peptide
    Liraglutide
    Outcome
    DecreaseSkilled reach motivation
    Study

    ratn: not reported in source

    Montoya staircase skilled reach test
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In rats with an acquired skilled reach performance, Ex4 or liraglutide but not dulaglutide reduced the motivation of skilled reach foraging.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats without prior Montoya experience, dulaglutide enhanced skilled reach foraging learning.

    In plain wordsIn rats without prior task experience, dulaglutide improved learning to reach for food.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseSkilled reach learning
    Study

    ratn: not reported in source

    Montoya staircase skilled reach test
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In rats without prior Montoya experience, dulaglutide but not Ex4 or liraglutide enhanced the learning of skilled reach foraging.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats without prior Montoya experience, liraglutide did not enhance skilled reach foraging learning.

    In plain wordsIn rats without prior task experience, liraglutide did not improve learning to reach for food.

    Peptide
    Liraglutide
    Outcome
    No significant changeSkilled reach learning
    Study

    ratn: not reported in source

    Montoya staircase skilled reach test
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In rats without prior Montoya experience, dulaglutide but not Ex4 or liraglutide enhanced the learning of skilled reach foraging.
  5. 05LabEx vivo tissueMechanism

    In rat tissue recordings, liraglutide suppressed evoked field potentials in the nucleus accumbens shell.

    In plain wordsIn lab tests of rat brain tissue, liraglutide reduced evoked electrical responses.

    Peptide
    Liraglutide
    Outcome
    DecreaseEvoked field potentials
    Study

    ratn: not reported in source

    Rat nucleus accumbens shell electrophysiology
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In trained rats, Ex4 infusion into NAc shell decreased this motivated behaviour, and both Ex4 and liraglutide supressed the evoked field potentials in NAc shell.
    1 context sentence
    Summary · context
    To explore the neurophysiological correlates of the different GLP-1R agonists on motivation, ex vivo electrophysiological recordings were conducted.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.